179 related articles for article (PubMed ID: 36266061)
1. Nivolumab with or without chemotherapy for metastatic gastroesophageal cancers and future perspectives.
Sewastjanow-Silva M; Yamashita K; Rosa Vicentini E; Hirschmann M; Pool Pizzi M; Trail AM; Waters RE; Rogers JE; Ajani JA
Expert Rev Anticancer Ther; 2022 Nov; 22(11):1177-1181. PubMed ID: 36266061
[TBL] [Abstract][Full Text] [Related]
2. Who Should Receive Immunotherapy for Advanced Gastroesophageal Cancer?
Khateeb S; Cavalcante L; Alnairat N; Singh M; Sahin IH; Saeed A; Saeed A
Curr Treat Options Oncol; 2024 Apr; 25(4):496-509. PubMed ID: 38372852
[TBL] [Abstract][Full Text] [Related]
3. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.
Moehler M; Högner A; Wagner AD; Obermannova R; Alsina M; Thuss-Patience P; van Laarhoven H; Smyth E
Eur J Cancer; 2022 Nov; 176():13-29. PubMed ID: 36183651
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in esophagogastric cancer.
Ilson DH
Clin Adv Hematol Oncol; 2021 Oct; 19(10):639-647. PubMed ID: 34637430
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy.
Smyth EC; Gambardella V; Cervantes A; Fleitas T
Ann Oncol; 2021 May; 32(5):590-599. PubMed ID: 33609722
[TBL] [Abstract][Full Text] [Related]
6. Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer.
Kadono T; Yamamoto S; Kato K
Jpn J Clin Oncol; 2022 Oct; 52(10):1089-1096. PubMed ID: 36047845
[TBL] [Abstract][Full Text] [Related]
7. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
Taieb J; Moehler M; Boku N; Ajani JA; Yañez Ruiz E; Ryu MH; Guenther S; Chand V; Bang YJ
Cancer Treat Rev; 2018 May; 66():104-113. PubMed ID: 29730461
[TBL] [Abstract][Full Text] [Related]
8. Current state of the art: immunotherapy in esophageal cancer and gastroesophageal junction cancer.
Li N; Sohal D
Cancer Immunol Immunother; 2023 Dec; 72(12):3939-3952. PubMed ID: 37995002
[TBL] [Abstract][Full Text] [Related]
9. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
Bilgin B; Sendur MA; Bülent Akıncı M; Şener Dede D; Yalçın B
Curr Med Res Opin; 2017 Apr; 33(4):749-759. PubMed ID: 28055269
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in Gastric Cancer.
Högner A; Moehler M
Curr Oncol; 2022 Mar; 29(3):1559-1574. PubMed ID: 35323331
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials.
Huynh J; Patel K; Gong J; Cho M; Malla M; Parikh A; Klempner S
Curr Treat Options Oncol; 2021 Sep; 22(11):100. PubMed ID: 34524553
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab combination therapy as first-line treatments for unresectable, advanced or metastatic esophageal squamous cell carcinoma.
Rogers JE; Yamashita K; Sewastjanow-Silva M; Rosa Vicentini E; Waters R; Ajani JA
Expert Rev Anticancer Ther; 2023 Jun; 23(6):565-571. PubMed ID: 37122102
[TBL] [Abstract][Full Text] [Related]
13. Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort.
Schlintl V; Huemer F; Rinnerthaler G; Melchardt T; Winder T; Reimann P; Riedl J; Amann A; Eisterer W; Romeder F; Piringer G; Ilhan-Mutlu A; Wöll E; Greil R; Weiss L
BMC Cancer; 2022 Jan; 22(1):51. PubMed ID: 35012477
[TBL] [Abstract][Full Text] [Related]
14. The safety of nivolumab for the treatment of metastatic melanoma.
O'Reilly A; Larkin J
Expert Opin Drug Saf; 2017 Aug; 16(8):955-961. PubMed ID: 28679287
[TBL] [Abstract][Full Text] [Related]
15. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
16. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for Esophageal and Gastric Cancer.
Kelly RJ
Am Soc Clin Oncol Educ Book; 2017; 37():292-300. PubMed ID: 28561677
[TBL] [Abstract][Full Text] [Related]
18. Current status of immunotherapy for advanced gastric cancer.
Kawazoe A; Shitara K; Boku N; Yoshikawa T; Terashima M
Jpn J Clin Oncol; 2021 Jan; 51(1):20-27. PubMed ID: 33241322
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang YK; Chen LT; Ryu MH; Oh DY; Oh SC; Chung HC; Lee KW; Omori T; Shitara K; Sakuramoto S; Chung IJ; Yamaguchi K; Kato K; Sym SJ; Kadowaki S; Tsuji K; Chen JS; Bai LY; Oh SY; Choda Y; Yasui H; Takeuchi K; Hirashima Y; Hagihara S; Boku N
Lancet Oncol; 2022 Feb; 23(2):234-247. PubMed ID: 35030335
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan.
Harada K; Yamamoto S; Kato K
Expert Opin Biol Ther; 2022 Nov; 22(11):1333-1338. PubMed ID: 36266954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]